secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-084251
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV Technologies reports additional positive Phase 3 VITESSE data for VIASKIN Peanut Patch at AAAAI 2026
--------------------------------------------------------------------------------

- 82.8% of treated children increased eliciting dose at month 12 vs ~48% placebo; 60.1% increased by ≥2 doses vs 23.4% placebo.
- 24% of placebo group decreased eliciting dose over 12 months vs 6.4% of treated group, indicating reduced sensitization.
- VIASKIN Peanut Patch was well tolerated; most adverse events were mild local application site reactions.
- Company plans to submit Biologics License Application (BLA) to FDA in the first half of 2026.
- All sensitivity analyses significant; response rate difference exceeded prespecified 15% threshold.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312526084251/0001193125-26-084251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312526084251/d110966d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-084251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer